Topic

Articles

Ariel Katz, CEO and co-founder of H1, talks about how to find the right KOL for the right audience at the right time.

Solving a 40-Plus-Year Healthcare Industry Puzzle: Ariel Katz, H1

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

Addressing the Pain Points with Emerging Technologies

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.


Breaking New Ground in Biopharma

After two decades at the forefront of hematology and oncology drug development, AbbVie’s vice president and global head of oncology clinical development, Mohamed Zaki, MD, PhD, is more hopeful than ever about recent advances in the space.

Oncology Optimist

Cyclacel CEO Spiro Rombotis talks about the changes he has seen during his 36-year experience in pharma and biotech and how he continues to be motivated by Cyclacel’s work on solid tumors and lymphomas.

A Marathon, Not a Sprint: Spiro Rombotis, CEO, Cyclacel

Elaine Quilici is Pharmaceutical Executive's Editor-in-Chief. Email her at equilici@mjhlifesciences.com

Moderna Chief Medical Officer Paul Burton looks to build on culture of innovation and speed to advance COVID-19 vaccine and develop new therapies based on its novel mRNA platform, spreading hope to patients around the world.

Crafting Cures

Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.





Avoiding the Shiny Penny Syndrome of Digital Transformation

Sajith Wickramasekara, co-founder and CEO of Benchling, talks about closing the gap between research and early-stage development to accelerate scientific breakthroughs in biopharma.





Q&A: Sajith Wickramasekara, Benchling

Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.

Q&A: Christian Wieszner, CSL Behring UK

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

Executive Profiles